ONCOLOGY & HAEMATOLOGY  ONCOLOGY & HAEMATOLOGY  ONCOLOGY & HAEMATOLOGY

 

Cinnapoietin

 

Cinnapoietin®

Description: Cinnapoietin® is a sterile, purified, stable recombinant human erythropoietin concentrate produced from genetically engineered Chinese hamster ovary (CHO) cells containing a cloned human erythropoietin gene, produced under EU GMP license. Dosage Forms and Strengths of Cinnapoietin® are 2000 IU, 4000 IU,10000 IU, 20000 IU and 40000 IU epoetin beta in prefilled syringes, which can be administrated by Intravenous or subcutaneous injection.

INN: Erythropoietin Beta

Indication: Anemic patients with Chronic Kidney Disease(CKD), Autologous Pre-Donation, Anemia of prematurity, Anemia due to chemotherapy in patients with non-myeloid malignancies

Protein type: Hormone

Mechanism of action: Erythropoietin is a glycoprotein that stimulates the formation of erythrocytes from its committed progenitors. It acts as a mitosis stimulating factor and differentiation hormone.

Cinnapoietin leaflet (PDF)

Neustim

Neustim®

Description: Neustim® is the brand name of pegfilgrastim and is supplied in 6 mg/0.6 mL prefilled syringes and autoinjectors (Physioject™) for subcutaneous injection

INN: Pegfilgrastim

Indication: Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome

Protein type: Haematopoietic growth factors

Mechanism of action: Stimulates the production, maturation, and activation of neutrophils, pegfilgrastim activates neutrophils to increase both their migration and cytotoxicity.

Neustim leaflet (PDF)

Zytux

Zytux®

Description: Zytux is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) infusion. It is provided in two dosages, 100 mg and 500 mg vial

INN: Rituximab

Indication: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

Protein type: Monoclonal antibody (mAb)

Mechanism of action: Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.

Zytux leaflet (PDF)

AryoTrust

AryoTrust™

Description: AryoTrust™ is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).

INN: Trastuzumab

Indication: HER2 over expressing early breast cancer, and metastatic gastric cancer

Protein type: Monoclonal antibody (mAb)

Mechanism of action: Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.

AryoTrust leaflet (PDF)

AryoSeven

AryoSeven™

Description: AryoSeven™, Human activated recombinant blood coagulation factor VII (rFVIIa), is a glycoprotein with 406 amino acids and molecular weight of about 50 KD, which is produced in Baby Hamster Kidney cell line (BHK) via recombinant technology and is highly purified to be acceptable as injectable human drug.

INN: Coagulation factor VIIa Recombinant Human

Indication: Hemophilia A or B with inhibitors, Acquired hemophilia, Congenital factor VII deficiency, Glanzmann's thrombasthenia

Protein type: Blood coagulation factors

Mechanism of action: Aryoseven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.

AryoSeven leaflet (PDF)

Stivant

Stivant™

Description: Stivant is supplied as a concentrate for solution for infusion in 4 milliliter and 16 milliliter vials containing 100 mg and 400 mg Bevaciuzmab, respectively. Each milliliter of concentrate contains 25 mg of Bevacizumab.

INN: Bevacizumab

Indication: As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.

Or

  • Metastatic colorectal cancer
  • Cervical cancer
  • Non-squamous cell Non-small cell lung cancer
  • Glioblastomas
  • Metastatic Renal Cell Carcinoma

Protein type: Monoclonal antibody (mAb)

Mechanism of action: Bevacizumab is designed to bind to VEGF extracellularly to prevent interaction with VEGF receptors on the surface of endothelial cells and inhibit VEGF's angiogenic activity.

Stivant leaflet (PDF)

 

Contact Us

 

© Singapore Biotechnology, Pte. Ltd. All rights reserved.